Fhit protein expression in human gastric cancer and related precancerous lesions

Oncology Reports

Volumn 8, Issue 6, 2001, Pages 1233-1237

  Caselli, Michele ^a   Marchisio, Marco ^a   Gaudio, Michele ^b   Saragoni, Luca ^b   Lanza, Giovanni ^a   Alvisi, Vittorio ^a   Bertagnolo, Valeria ^a   Concu, Manuela ^c   Capitani, Silvano ^a   Caramelli, Elisabetta ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

FHIT; Fhit protein immunostaining; Gastric carcinogenesis; RT PCR

Indexed keywords

ACID ANHYDRIDE HYDROLASE; FRAGILE HISTIDINE TRIAD PROTEIN; TUMOR PROTEIN;

ADENOCARCINOMA; AGED; ARTICLE; FEMALE; GENETICS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; PRECANCER; STOMACH TUMOR;

ACID ANHYDRIDE HYDROLASES; ADENOCARCINOMA; AGED; AGED, 80 AND OVER; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; STOMACH NEOPLASMS;

EID: 0035515237     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.8.6.1233     Document Type: Article

References (18)

1. Campiglio M, Pekarsky J, Menard S, Tagliabue E, Pilotti S and Croce CM: FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 59: 3866-3869, 1999.
2. Panagopoulos I, Pandis N, Thelin S, Pettersson C, Mertens F, Borg A, Kristoffersson U, Mitclman F and Aman P: The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res 56: 4871-4875, 1996.
3. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K and Croce CM: The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 56: 3173-3179, 1996.
4. Kisielewski AE, Xiao GH, Liu SC, Klein-Szanto AJP, Novara M, Sina J, Bleicher K, Yeung RS and Goodrow TL: Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck. Oncogene 17: 83-91, 1998.
5. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K and Croce CM: FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 93: 9770-9775, 1996.
6. Mao L, Fan YH, Lotan R and Hong WK: Frequent abnormalities of FHIT, a candidate tumor suppressor gene in head and neck cancer cell lines. Cancer Res 56: 5128-5131, 1996.
7. Michael D, Beer DG, Wilke CW, Miller DE and Glover TW: Frequent deletions of FHIT and FRA3B in Barren's metaplasia and esophageal adenocarcinomas. Oncogene 15: 1653-1659, 1997.
8. Tanaka H, Shimada Y, Harada H, Shinoda M, Hatooka S, Imamura M and Ishizaki K: Methylation of the 5′ CpG islan of the FHIT gene is closeely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res 58: 3429-3434, 1998.
9. Xiao GH, Jin F, Klein-Szanto AJP, Goodrow TL, Linchan MW and Jeung RS: The FHIT gene product is highly expressed in the cytoplasm of renal tubular epithelium and is down regulated in kidney cancers. Am J Pathol 151: 1541-1547, 1997.
10. Baffa R, Cornella LG, Vecchione A, Bassi P, Mimori K, Sedor J, Calviello CM, Gardiman M, Minimo C, Strup SE, McCue PA, Kovatich AJ, Pagano F, Huebner K and Croce CM: Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol 156:419-424,2000.
11. Geurts JM, Schoenmakers EF, Roijer E, Stenman G and van de Yen WJ: Expression of reciprocal hybrid transcripts of HMGIC and FHIT in a pleorhorphic adenoma of parotid gland. Cancer Res 57: 13-17, 1997.
12. Sozzi G, Veronese M L, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K and Croce CM: The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 85: 17-26, 1996.
13. Burke L, Khan MA, Freedman AN, Gemma A, Rusin M, Guinee DG, Bennett WP, Caporaso NE, Fleming MV, Travis WD, Cplby TV, Trastek V, Pairolero PC, Tazelaar HD, Midthun DE, Liolta LA and Harris CC: Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res 58: 2533-2536, 1998.
14. Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ and Geradts J: Abnormal FHIT expression in malignant and premalignant lesions of the cervix. Cancer Res 59: 5270-5274, 1999.
15. Ozaki K, Enomoto T, Yoshino K, Hongbo S, Nakamura T, Fujita M, Kuragaki C, Sakata M, Kurachi H and Murata Y: Fhit alterations in endometrial carcinoma and hyperplasia. Int J Cancer 85: 306-312, 2000.
16. Sorio C, Baron A, Orlandini S, Zamboni G, Pederzoli P, Huebner K and Scarpa A: The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. Cancer Res 59: 1308-1314, 1999.
17. Gemma A, Hagiwara K, Ke Y, Burke LM, Khan MA, Nagashima M, Bennett WP and Harris CC: FHIT mutations in human primary gastric cancer. Cancer 57: 1435-1437, 1997.
18. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM and Huebner K: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t (3;8) break point, is abnormal in digestive tract cancer. Cell 84: 587-597, 1996.